Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07783581 | Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial | not yet recruiting | Phase 2 | 30 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK |
| 8 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04310020 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | active not recruiting | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 57 | Yonsei UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT05979298 | Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 2 | 40 | CureLab OncologyINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | suspended | Phase 2 | 63 | Duke UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 24, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)(NeoTILs) | recruiting | Phase 2 | 55 | Medical University of South CarolinaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer(MODeFIRe-1) | recruiting | Phase 2 | 25 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781072 | Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer(MELIA) | not yet recruiting | Phase 2 | 128 | Tongji HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 159 | Yale UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | recruiting | Phase 2 | 350 | Acrivon TherapeuticsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | suspended | Phase 2 | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06432036 | Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | recruiting | Phase 1 / Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06441890 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer(BRE-10) | recruiting | Phase 2 | 28 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation(EMPIRE) | recruiting | Phase 2 | 20 | Benjamin SpielerOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06844383 | A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide(TALENT) | recruiting | Phase 2 | 126 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07321015 | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance(Fzp-MA-TNBC) | recruiting | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07581405 | GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer | not yet recruiting | Phase 2 | 26 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07778940 | Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.(LEP-THP-2026) | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | active not recruiting | Phase 2 | 46 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04933903 | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | recruiting | Phase 2 | 25 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT05557877 | Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer | recruiting | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 25, 2026source: clinicaltrials